पाज़ोपैनिब और क्विनिडिन का इंटरैक्शन

Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP.

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval.

Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] .

Transporters Coadministration of strong inhibitors of P-gp or BCRP may increase pazopanib concentrations.

Consider selection of alternative concomitant medicinal products with no or minimal potential to inhibit P-gp or BCRP.